US FDA Uses PI3K Inhibitor Experience To Spell Out What It Wants In Dose Optimization Studies

 
• By Sue Sutter
  
Eye glasses
FDA wants oncology sponsors to get a clearer picture of the safety, tolerability and efficacy of multiple doses earlier in development. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers